caa a22 4500 469026731 CHVBK 20180323132732.0 cr unu---uuuuu 170328e19920401xx s 000 0 eng 10.1007/BF01980483 doi (NATIONALLICENCE)springer-10.1007/BF01980483 Is Recormon® less painful than Eprex® after subcutaneous administration? [Elektronische Daten] [M. Hendriks, F. Peters, P. Hooymans, T. Van de Wiel, D. Janknegt, R. Janknegt, J. Lohman] In this study, we examined the differences in pain score after subcutaneous injection of the epoetin preparations Eprex® and Recormon®. Patients (n=30) received 5 injections Eprex® and 5 injections Recormon® in a randomized double-blind sequence. 10 Min after receiving the injection the patient was asked to complete a visual and a verbal analogue scale and two descriptive scales. The results of 25 patients were used for statistical evaluation. The overall results indicate that there are significantly more patients reporting pain after subcutaneous injection of Eprex® than after Recormon® (11 versus 2 patients, p <0.05; McNemar test). 12 Patients reported no differences in pain. 43 Out of 123 injections Eprex® and 69 out of 125 injections Recormon® caused no pain (p <0.01; χ2 9.455). For 4 patients Recormon® was significantly (p < 0.05) less painful than Eprex®. It can be concluded that Recormon® may be a less painful alternative for individual patients reporting pain after subcutaneous injection of Eprex®. Royal Dutch Association for Advancement of Pharmacy, 1992 Epoetin nationallicence Injections, subcutaneous nationallicence Pain nationallicence Rating scales nationallicence Hendriks M. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut Peters F. Department of Internal Medicine, Maasland Hospital, Sittard aut Hooymans P. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut Van de Wiel T. Department of Internal Medicine, Maasland Hospital, Sittard aut Janknegt D. Emmen, the Netherlands aut Janknegt R. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut Lohman J. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut Pharmaceutisch Weekblad Kluwer Academic Publishers 14/2(1992-04-01), 55-58 0031-6911 14:2<55 1992 14 11096 https://doi.org/10.1007/BF01980483 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01980483 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hendriks M. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut NATIONALLICENCE 700 1- Peters F. Department of Internal Medicine, Maasland Hospital, Sittard aut NATIONALLICENCE 700 1- Hooymans P. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut NATIONALLICENCE 700 1- Van de Wiel T. Department of Internal Medicine, Maasland Hospital, Sittard aut NATIONALLICENCE 700 1- Janknegt D. Emmen, the Netherlands aut NATIONALLICENCE 700 1- Janknegt R. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut NATIONALLICENCE 700 1- Lohman J. Department of Clinical Pharmacy and Toxicology, Maasland Hospital, P.O. Box 5500, 6130, MB Sittard, the Netherlands aut NATIONALLICENCE 773 0- Pharmaceutisch Weekblad Kluwer Academic Publishers 14/2(1992-04-01), 55-58 0031-6911 14:2<55 1992 14 11096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer